Nishina, Tomohiro
Shikoku Cancer Center
12 papers on CoChatORCID 0000-0002-4073-3757
Most cited papers
- Verified
Clinical utility of circulating tumor DNA sequencing in advanced gastrointestinal cancer: SCRUM-Japan GI-SCREEN and GOZILA studies
Nakamura, Y., Taniguchi, H., Ikeda, M., Bando, H., Kato, K., Morizane, C., Esaki, T., Komatsu, Y., Kawamoto, Y., Takahashi, N., et al. (2020) · Nature Medicine
Cancer Genomics and DiagnosticsColorectal Cancer Treatments and Studies
Cited by 373
- Verified
TAS-102 monotherapy for pretreated metastatic colorectal cancer: a double-blind, randomised, placebo-controlled phase 2 trial
Yoshino, T., Mizunuma, N., Yamazaki, K., Nishina, T., Komatsu, Y., Baba, H., Tsuji, A., Yamaguchi, K., Muro, K., Sugimoto, N., et al. (2012) · The Lancet Oncology
Colorectal Cancer Treatments and StudiesColorectal Cancer Surgical Treatments
Cited by 326
- Verified
Circulating tumor DNA-guided treatment with pertuzumab plus trastuzumab for HER2-amplified metastatic colorectal cancer: a phase 2 trial
Nakamura, Y., Okamoto, W., Kato, T., Esaki, T., Kato, K., Komatsu, Y., Yuki, S., Masuishi, T., Nishina, T., Ebi, H., et al. (2021) · Nature Medicine
Colorectal Cancer Treatments and StudiesCancer Genomics and Diagnostics
Cited by 231
- Verified
Final results of DESTINY-CRC01 investigating trastuzumab deruxtecan in patients with HER2-expressing metastatic colorectal cancer
Yoshino, T., Di Bartolomeo, M., Raghav, K., Masuishi, T., Loupakis, F., Kawakami, H., Yamaguchi, K., Nishina, T., Wainberg, Z., Elez, E., et al. (2023) · Nature Communications
Colorectal Cancer Treatments and StudiesHER2/EGFR in Cancer Research
Cited by 178
- Verified
Multicenter phase I/II trial of napabucasin and pembrolizumab in patients with metastatic colorectal cancer (EPOC1503/SCOOP trial)
Kawazoe, A., Kuboki, Y., Shinozaki, E., Hara, H., Nishina, T., Komatsu, Y., Yuki, S., Wakabayashi, M., Nomura, S., Sato, A., et al. (2020) · Clinical Cancer Research
Cancer Immunotherapy and BiomarkersColorectal Cancer Treatments and Studies
Cited by 93
- Verified
Clinical significance of BRAF non-V600E mutations on the therapeutic effects of anti-EGFR monoclonal antibody treatment in patients with pretreated metastatic colorectal cancer: the Biomarker Research for anti-EGFR monoclonal Antibodies by Comprehensive Cancer genomics (BREAC) study
Shinozaki, E., Yoshino, T., Yamazaki, K., Muro, K., Yamaguchi, K., Nishina, T., Yuki, S., Shitara, K., Bando, H., Mimaki, S., et al. (2017) · British Journal of Cancer
Colorectal Cancer Treatments and StudiesLung Cancer Treatments and Mutations
Cited by 65
- Verified
A phase II, multicenter, open-label study of trastuzumab deruxtecan (T-DXd; DS-8201) in patients (pts) with HER2-expressing metastatic colorectal cancer (mCRC): DESTINY-CRC01.
Siena, S., Di Bartolomeo, M., Raghav, K. P. S., Masuishi, T., Loupakis, F., Kawakami, H., Yamaguchi, K., Nishina, T., Fakih, M., Elez, E., et al. (2020) · Journal of Clinical Oncology
Colorectal Cancer Treatments and StudiesHER2/EGFR in Cancer Research
Cited by 54
- Verified
HER2-related biomarkers predict clinical outcomes with trastuzumab deruxtecan treatment in patients with HER2-expressing metastatic colorectal cancer: biomarker analyses of DESTINY-CRC01
Siena, S., Raghav, K., Masuishi, T., Yamaguchi, K., Nishina, T., Elez, E., Rodriguez, J., Chau, I., Di Bartolomeo, M., Kawakami, H., et al. (2024) · Nature Communications
Colorectal Cancer Treatments and StudiesHER2/EGFR in Cancer Research
Cited by 30
- Verified
Randomised Phase II Study of Panitumumab plus Irinotecan versus Cetuximab plus Irinotecan in Patients with KRAS Wild-Type Metastatic Colorectal Cancer Refractory to Fluoropyrimidine, Irinotecan and Oxaliplatin (WJOG 6510G)
Sakai, D., Taniguchi, H., Sugimoto, N., Tamura, T., Nishina, T., Hara, H., Esaki, T., Denda, T., Sakamoto, T., Okuda, H., et al. (2020) · European Journal of Cancer
Colorectal Cancer Treatments and StudiesColorectal Cancer Surgical Treatments
Cited by 23
- Verified
Clinical features associated with NeoRAS wild-type metastatic colorectal cancer A SCRUM-Japan GOZILA substudy
Osumi, H., Shinozaki, E., Nakamura, Y., Esaki, T., Yasui, H., Taniguchi, H., Satake, H., Sunakawa, Y., Komatsu, Y., Kagawa, Y., et al. (2024) · Nature Communications
Colorectal Cancer Treatments and StudiesCancer Genomics and Diagnostics
Cited by 17
- Verified
Clinical Validation of Plasma-Based Genotyping for RAS and BRAF V600E Mutation in Metastatic Colorectal Cancer: SCRUM-Japan GOZILA Substudy
Aoki, Y., Nakamura, Y., Denda, T., Ohta, T., Esaki, T., Shiozawa, M., Yamaguchi, K., Yamazaki, K., Sunakawa, Y., Kato, T., et al. (2023) · JCO Precision Oncology
Colorectal Cancer Treatments and StudiesCancer Genomics and Diagnostics
Cited by 11
- Verified
Novel ERBB2 Variant Potentially Associated with Resistance against Anti-HER2 Monoclonal Antibody–Based Therapy in ERBB2 -Amplified Metastatic Colorectal Cancer
Iida, N., Imai, M., Okamoto, W., Kato, T., Esaki, T., Kato, K., Komatsu, Y., Yuki, S., Masuishi, T., Nishina, T., et al. (2024) · Clinical Cancer Research
HER2/EGFR in Cancer ResearchColorectal Cancer Treatments and Studies
Cited by 2
Go further with a free account
Verify every reference, keep papers in a library, and ask questions across them.
Sign up - it is free